Keyphrases
Endometrial Adenocarcinoma
100%
Cisplatin
100%
Adriamycin
100%
Cyclophosphamide
100%
Postoperative Adjuvant Chemotherapy
100%
Carboplatin-paclitaxel
100%
Response Rate
33%
Complete Response
22%
Partial Response
22%
Progression-free Survival
22%
Paclitaxel
11%
Thrombocytopenia
11%
No Significant Difference
11%
Overall Survival
11%
Antitumor Activity
11%
Toxic Effects
11%
Adjuvant Chemotherapy
11%
Chemotherapy Regimen
11%
Overall Survival Rate
11%
Combination Chemotherapy
11%
Obstetrics
11%
Gastrointestinal Toxicity
11%
Conventional Chemotherapy
11%
Stage III-IV
11%
International Federations
11%
National Cancer Institute
11%
Toxicity Profile
11%
Common Toxicity Criteria
11%
Patient Response
11%
Activity Effect
11%
Pharmacology, Toxicology and Pharmaceutical Science
Paclitaxel
100%
Chemotherapy
100%
Endometrium Carcinoma
100%
Cisplatin
100%
Doxorubicin
100%
Cyclophosphamide
100%
Carboplatin
100%
Overall Survival
22%
Progression Free Survival
22%
Malignant Neoplasm
11%
Survival Rate
11%
Thrombocytopenia
11%
Antitumor Activity
11%
Gastrointestinal Toxicity
11%
Toxicity
11%
Chemotherapy Regimens
11%